• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lancet Says Industry is 'Medicalizing' Everyday Problems

Lancet Says Industry is 'Medicalizing' Everyday Problems

February 23, 2007
CenterWatch Staff

A group of healthcare experts have published a series of six essays in the British medical journal Lancet discussing direct-to-consumer (DTC) advertising and what they see as the 'Medicalizing' of modern society. HealthDay Reporter Ed Edelson explores the issue in a well-balanced piece published yesterday at HealthDay News.

You can read the story here or by continuing reading below:


Outside Forces 'Medicalizing' Everyday Problems, Experts Say
Drug ads and other factors are having an impact on clinical practice

By Ed Edelson
HealthDay Reporter

THURSDAY, Feb. 22 (HealthDay News) -- Consumers, often egged on by drug ads they see on television and elsewhere, are "medicalizing" what doctors may have previously not considered full clinical problems, experts write in this week's issue of the journal The Lancet.

The trend has both its upside and downside, experts say.

In the 1970s, the term medicalization "came into being as a critique of the power of doctors, who, in the guise of treatment, were doing things that were bad for people," said Dr. Jonathan Metzl, associate professor of psychiatry and women's studies at the University of Michigan.

"The term has expanded greatly in its use. Today, it is used more in connection with the actions of pharmaceutical companies, and we need to understand its effects better," he said.

Metzl discussed the effects of direct-to-consumer (DTC) drug advertising in one of six essays in the journal, originating from a workshop on medicalization that he helped organize.

"Pharmaceutical advertisements definitely have pushed the boundaries of what is and what is not considered a medical issue," the expert said.

For example, television advertisements for Cialis, Levitra and Viagra have changed the perception of what it is to be a normal, healthy man, Metzl said. In that way, male sexual performance has been "medicalized."

Similarly, DTC antidepressant ads that depict depressed women as unable to fulfill their roles in the family have medicalized that issue, Metzl said.

"It's hard to deal with them, because we are so overwhelmed by these advertisements," he said. "But I don't think we should reject them out of hand. We should think of what they say about illness and health."

On the part of the consumer, such advertisements "can engender useful conversations between doctors and patients," Metzl said. "And they can encourage doctors to look at cultural issues."

Other essays touched on different aspects of the issue. For example, Troy Duster, professor of sociology at New York University, wrote about the medicalization of race -- specifically, about the approval in the United States of medications designed specifically for black Americans.

"The appearance of racialized drugs on pharmacist's shelves only increases the need to attend to the myriad social sources of disparities in morbidity and mortality," Duster wrote. "Although to turn a profit from fighting racial discrimination is difficult, effective medical care requires continued awareness of the complex social dimensions of diseases, such as hypertension and cancer."

Cindy Patton, professor of sociology and anthropology at Simon Fraser University in Vancouver, Canada, wrote of changes that have occurred in the evolution of treatment of HIV/AIDS because of the new accent on medicalization.

Because of the impact of HIV care on other aspects of health -- for example, cardiovascular well-being -- HIV-positive patients and their doctors are increasingly aware of trends across a wide variety of medical specialities. In many cases, these specialities -- such as virology and cardiovascular disease -- used to have little in common, Patton explained.

However, "The distance between biomedical specialties that might once have been bridged mainly by researchers and specialized clinicians now is negotiated mainly by the patients themselves, since their knowledge sets expand and intertwine over time," she wrote.

More information

There's more on DTC drug advertising at the U.S. Food and Drug Administration.

SOURCES: Jonathan Metzl, M.D., associate professor, psychiatry and women's studies, University of Michigan, Ann Arbor; Feb. 24, 2007, The Lancet

Last Updated: Feb. 22, 2007

Copyright © 2007 ScoutNews, LLC. All rights reserved.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing